Clinical significance of combination study of apoptotic factors and proliferating cell nuclear antigen in estimating the prognosis of hepatocellular carcinoma

2003 ◽  
Vol 85 (1) ◽  
pp. 48-54 ◽  
Author(s):  
Shinji Osada ◽  
Shigetoyo Saji ◽  
Toshiya Kuno
Keyword(s):  
Hepatocellular Carcinoma ◽  
Clinical Significance ◽  
Proliferating Cell Nuclear Antigen ◽  
Nuclear Antigen ◽  
Combination Study ◽  
Proliferating Cell ◽  
Apoptotic Factors

scholarly journals Phosphorylation of p53 Serine 15 Is a Predictor of Survival for Patients with Hepatocellular Carcinoma

2019 ◽  
Vol 2019 ◽  
pp. 1-8 ◽  
Author(s):  
Taewoo Yang ◽  
Yegyun Choi ◽  
Jae Won Joh ◽  
Steve K. Cho ◽  
Dae-Shick Kim ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Proliferating Cell Nuclear Antigen ◽  
Prognostic Value ◽  
Nuclear Antigen ◽  
Survival Outcomes ◽  
P53 Expression ◽  
Immunohistochemical Markers ◽  
Prognostic Utility ◽  
Poor Outcomes ◽  
Proliferating Cell

Background. Hepatocellular carcinoma (HCC) is one of the most common malignant cancers with a poor prognosis. Several commonly investigated immunohistochemical markers in resected HCC have potential prognostic value, but the prognostic utility of p53 expression in HCC has remained elusive. Aim. To evaluate the prognostic value of p53 and p53 phosphorylation at serine 15 (p53 Ser15-P) in patients with HCC. Methods. Surgically resected tumors from 199 HCC patients were analyzed for p21, p53, p53 Ser15-P, and proliferating cell nuclear antigen (PCNA) expression using immunohistochemistry. Results. Stratifying by the expression of p53 Ser15-P (P = 0.016), but not by p53 (P = 0.301), revealed significantly different survival outcomes in patients with HCC. Moreover, our analysis demonstrated that patients who were PCNA-positive and p53 Ser15-P–negative had significantly worse survival outcomes (P = 0.001) than patients who were PCNA-positive and p53 Ser15-P–positive. Conclusions. P53 Ser15-P is associated with poor outcomes in patients with HCC, and this prognostic marker is useful for predicting the survival of patients with PCNA-positive HCC.

The clinical significance of autoantibodies to the proliferating cell nuclear antigen (PCNA)

2012 ◽  
Vol 11 (10) ◽  
pp. 771-775 ◽  
Author(s):  
Michael Mahler ◽  
Kiyomitsu Miyachi ◽  
Carol Peebles ◽  
Marvin J. Fritzler
Keyword(s):  
Clinical Significance ◽  
Proliferating Cell Nuclear Antigen ◽  
Nuclear Antigen ◽  
Proliferating Cell
Sign in / Sign up

Export Citation Format

Share Document